The prevalence of Alzheimer's disease (AD) in the U.S. is more than 5 million today and estimated to increase to 14 million by 2050. We now know that the underlying pathology that causes dementia in AD patients is simmering in the brain for decades before it becomes symptomatically evident in patients.
AgeneBio's clinical therapy is directed at Mild Cognitive Impairment (MCI), a stage that is intermediate between normal cognition and dementia when an older person’s memory/cognition is worse than would be expected for his/her age. No therapy to treat MCI, either symptomatically or to slow progression in Alzheimer’s disease to dementia, has yet received FDA approval, representing a critical unmet need for a large and growing population of patients.
Develop therapies to improve and preserve cognition and to slow or prevent progression of cognitive impairment in aging, including MCI, based on the innovative science of our founder, Michela Gallagher, PhD, a global leader in the field of neuroscience, cognition and aging.